Children with diffuse midline glioma who took Keppra lived a median of 20.96 months, compared with 9.92 months for those who did not, a new study found.
|Videos|December 14, 2016
Sumul Raval Tells Patients With GBM, "I'm Your Quarterback"
Author(s)Sumul Raval, M.D.
Sumul N. Raval, M.D., founder and director of the Zocchi Brain Tumor Center at Monmouth Medical Center and 2016 GBM hero, tells his patients, "I'm your quarterback."
Advertisement
Sumul N. Raval, M.D., founder and director of the Zocchi Brain Tumor Center at Monmouth Medical Center and 2016 GBM hero, tells his patients, "I'm your quarterback."
Brain tumors like glioblastoma are difficult to treat, and involve treating not only the patient, but the whole family. Raval wants his patients to know that they can call him day or night for any concerns.
Advertisement
Related to this article
Deborah A. McDowell of OAW explains how patients can prepare for hair loss before chemotherapy starts.
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
Dr. Miguel Gonzales-Velez explains how placebos are used in phase 3 cancer trials, and why joining one does not mean giving up standard treatment.
Advertisement
Advertisement
Trending on CURE
1
5 Years of Leukemia Advances: A Timeline of FDA Approvals and What They Mean for Patients
2
3 More Lung Cancer Breakthroughs From WCLC 2026
3
Blood Cancer Treatments in the FDA Pipeline: What Could Come Next
4
Oncology Nurse Leader Brings Stem Cell Transplant Care Closer to Home
5